Navigation Links
Lilly Declares Third-Quarter Dividend
Date:6/20/2008

INDIANAPOLIS, June 20 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2008 of $0.47 a share on outstanding common stock. This is the same dividend as was paid in the first and second quarters and maintains the annual indicated dividend rate for 2008 of $1.88 per share.

The dividend is payable September 10, 2008, to shareholders of record at the close of business on August 15, 2008.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Pitt study suggests craving hinders comprehension without your realizing it 2Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5Health News:Pitt study suggests craving hinders comprehension without you realizing it 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3
Other Medicine News:Health News:Julie L. Novak Named Executive Director of Michigan State Medical Society 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 8Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 9Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 10Health News:National Health Care Coalition Commends New Congress' Focus on Fighting Chronic Disease in House Stimulus Package 2Health News:Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009 2Health News:Optelec and ShopLowVision.com Bring Life Back Into Focus at ATIA 2009 Orlando 2Health News:Optelec and ShopLowVision.com Bring Life Back Into Focus at ATIA 2009 Orlando 3Health News:Patients' Bath Basins Increase Risk for Hospital-Acquired Infections 2Health News:Patients' Bath Basins Increase Risk for Hospital-Acquired Infections 3
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Weight Loss Surgery Breaks Families Obesity Cycle 55987 1Weight Loss Surgery Breaks Families Obesity Cycle 55987 2Dr William J Robbins Joins Anpath Group Inc Board of Directors 55984 1Dr William J Robbins Joins Anpath Group Inc Board of Directors 55984 2Dr William J Robbins Joins Anpath Group Inc Board of Directors 55984 3Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 1Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 2Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 3
Other Medicine Technology:VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 2New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 3New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 4New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 5New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 6